George Robert Wellman Joins Scientific Advisory Board of Ricerca, LLC

Apr 24, 2001, 01:00 ET from Ricerca, LLC

    CONCORD, Ohio, April 24 /PRNewswire Interactive News Release/ -- Ricerca,
 LLC, a drug development company, has announced the appointment of George
 Robert Wellman, Ph.D., to its Scientific Advisory Board.  "Dr. Wellman's
 insights from his distinguished career in pharmaceutical chemical development
 make him a wonderful addition to our advisory board," said Dr. Prabhavathi
 Fernandes, Ricerca CEO.  "His successes in the development of commercial
 processes for drugs such as Tagamet(R) will be an invaluable resource for the
 continual improvement of our very successful process chemistry and
 pharmaceutical development and engineering business."
     Dr. Wellman retired from SmithKline Beecham Pharmaceuticals in January,
 where he was vice president, chemical development worldwide.  As such, he was
 responsible for all chemical development operations at five SmithKline Beecham
 sites throughout the world, transferring technology and supporting the
 manufacturing division at many sites.  Prior to this position he held a number
 of titles at SmithKline Beecham, including vice president, chemical
 development, group director of development chemistry and director of synthetic
 chemistry.
     Dr. Wellman has authored 41 technical publications, 10 patents and
 presentations.  He is a member of the American Chemical Society, American
 Association for the Advancement of Science, Philadelphia Organic Chemists
 Club, New York Academy of Science and the American Institute of Chemical
 Engineers.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X16121192
 
 

SOURCE Ricerca, LLC
    CONCORD, Ohio, April 24 /PRNewswire Interactive News Release/ -- Ricerca,
 LLC, a drug development company, has announced the appointment of George
 Robert Wellman, Ph.D., to its Scientific Advisory Board.  "Dr. Wellman's
 insights from his distinguished career in pharmaceutical chemical development
 make him a wonderful addition to our advisory board," said Dr. Prabhavathi
 Fernandes, Ricerca CEO.  "His successes in the development of commercial
 processes for drugs such as Tagamet(R) will be an invaluable resource for the
 continual improvement of our very successful process chemistry and
 pharmaceutical development and engineering business."
     Dr. Wellman retired from SmithKline Beecham Pharmaceuticals in January,
 where he was vice president, chemical development worldwide.  As such, he was
 responsible for all chemical development operations at five SmithKline Beecham
 sites throughout the world, transferring technology and supporting the
 manufacturing division at many sites.  Prior to this position he held a number
 of titles at SmithKline Beecham, including vice president, chemical
 development, group director of development chemistry and director of synthetic
 chemistry.
     Dr. Wellman has authored 41 technical publications, 10 patents and
 presentations.  He is a member of the American Chemical Society, American
 Association for the Advancement of Science, Philadelphia Organic Chemists
 Club, New York Academy of Science and the American Institute of Chemical
 Engineers.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X16121192
 
 SOURCE  Ricerca, LLC